Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease ...Middle East

- European Commission decision anticipated in beginning of May 2023 - PARMA, Italy and BOSTON and CARMIEL, Israel, Feb. 24, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...

Hence then, the article about chiesi global rare diseases and protalix biotherapeutics receive positive chmp opinion for pegunigalsidase alfa for treatment of fabry disease was published today ( Friday 24/02/2023 - 05:28 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease )

Also on site :

• ‘Modern Family’ Star Reveals Why He Changed His Mind About Filming a Spinoff
• Trump’s loss of $1.7 trillion in tariff revenue will send the national debt to $58 trillion by 2036, think tank projects
• Dunkin’s At Home Line Expands With New Espresso Options